Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer

Endocrine-Related Cancer

Volumn 21, Issue 6, 2014, Pages 831-844

  Schock, Helena ^a,b   Surcel, Heljä Marja ^c   Zeleniuch Jacquotte, Anne ^d   Grankvist, Kjell ^b   Lakso, Hans Åke ^b   Fortner, Reneé Turzanski ^a   Kaaks, Rudolf ^a   Pukkala, Eero ^e,f   Lehtinen, Matti ^f   Toniolo, Paolo ^d,g   Lundin, Eva ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UMEÅ UNIVERSITY   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e FINNISH CANCER REGISTRY   (Finland)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Case control study; Ovarian neoplasms; Pregnancy; Prospective study; Sex steroids

Indexed keywords

SEX HORMONE; TUMOR MARKER;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; MIDDLE AGED; OVARIAN NEOPLASMS; PREGNANCY; PROGNOSIS; PROSPECTIVE STUDY; TUMOR INVASION; YOUNG ADULT;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREGNANCY; PROGNOSIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84919615342     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0282     Document Type: Article

References (54)

1. Adami HO,Hsieh CC, LambeM, Trichopoulos D, Leon D, Persson I,EkbomA & Janson PO 1994 Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344 1250-1254. (doi:10.1016/S0140-6736(94)90749-8)
2. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH, Onland-Moret NC, Lahmann PH, Berrino F et al. 2008 Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer 15 485-497. (doi:10.1677/ERC-07-0064)
3. Auersperg N, Wong AS, Choi KC, Kang SK& Leung PC 2001 Ovarian surface epithelium: biology, endocrinology, and pathology. Endocrine Reviews 22 255-288. (doi:10.1210/edrv.22.2.0422)
4. Barlow L, Westergren K, Holmberg L & Talback M 2009 The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncologica 48 27-33. (doi:10.1080/02841860802247664)
5. Bodmer M, Becker C, Meier C, Jick SS & Meier CR 2011 Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecologic Oncology 123 200-204. (doi:10.1016/j.ygyno.2011.06.038)
6. Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC & Correa CN 2003 Pathology and classification of ovarian tumors. Cancer 97 2631-2642. (doi:10.1002/cncr.11345)
7. Cleveland WS & Loader C 1996 Smoothing by local regression: principles and methods. In Statistical Theory and Computational Aspects of Smoothing, pp 10-49. Eds W Haerdle & MG Schimek. Heidelberg: Physica-Verlag.
8. Conklin CM & Gilks CB 2013 Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. Expert Review of Obstetrics & Gynecology 8 67-82. (doi:10.1586/eog.12.72)
9. Cramer DW & Xu H 1995 Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Annals of Epidemiology 5 310-314. (doi:10.1016/1047-2797(94)00098-E)
10. Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA & Lange CA 2013 Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle 12 1433-1449. (doi:10.4161/cc.24550)
11. Edmondson RJ, Monaghan JM & Davies BR 2002 The human ovarian surface epithelium is an androgen responsive tissue. British Journal of Cancer 86 879-885. (doi:10.1038/sj.bjc.6600154)
12. Escobar JC, Patel SS, Beshay VE, Suzuki T & Carr BR 2011 The human placenta expresses CYP17 and generates androgens de novo. Journal of Clinical Endocrinology and Metabolism 96 1385-1392. (doi:10.1210/jc.2010-2504)
13. Fathalla MF 1971 Incessant ovulation - a factor in ovarian neoplasia? Lancet 2 163. (doi:10.1016/S0140-6736(71)92335-X)
14. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F 2014. Globocan 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11.
15. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC & Comstock GW 1995 Serum gonadotropins and steroid hormones and the development of ovarian cancer. Journal of the American Medical Association 274 1926-1930. (doi:10.1001/jama.1995.03530240036037)
16. Holl K, Lundin E, Kaasila M, Grankvist K, Afanasyeva Y, Hallmans G, Lehtinen M, Pukkala E, Surcel HM, Toniolo P et al. 2008 Effect of longterm storage on hormone measurements in samples from pregnant women: the experience of the Finnish Maternity Cohort. Acta Oncologica 47 406-412. (doi:10.1080/02841860701592400)
17. Kurman RJ & Shih IM 2010 The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology 34 433-443. (doi:10.1097/PAS.0b013e3181cf3d79)
18. Kurman RJ& Shih IM2011 Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Human Pathology 42 918-931. (doi:10.1016/j.humpath.2011.03.003)
19. Lee KR, Tavassoli FA, Prat J, Dietel M, GersellDJ, Karseladze AI,Hauptmann S, Rutgers J, Russel P, Buckley CH et al. 2003 Tumors of the ovary and peritoneum. In Pathology and Genetics Tumours of the Breast and Female GenitalOrgans,pp113-202.EdsFATavassoli&PDevilee.Lyon: IARCPress.
20. Lim D & Oliva E 2013 Precursors and pathogenesis of ovarian carcinoma. Pathology 45 229-242. (doi:10.1097/PAT.0b013e32835f2264)
21. Lukanova A & Kaaks R 2005 Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiology, Biomarkers & Prevention 14 98-107.
22. Lukanova A, Lundin E, Akhmedkhanov A, Micheli A, Rinaldi S, Zeleniuch- Jacquotte A, Lenner P, Muti P, Biessy C, Krogh V et al. 2003 Circulating levels of sex steroid hormones and risk of ovarian cancer. International Journal of Cancer 104 636-642. (doi:10.1002/ijc.10990)
23. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, Krogh V, Lenner P, Shore RE, Biessy C et al. 2004 Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. International Journal of Cancer 108 425-432. (doi:10.1002/ijc.11529)
24. Mall-Haefeli M, Werner-Zodrow I, Huber PR, Darragh A & Lambe R 1983 Effects of various combined oral contraceptives on sex steroids, gonadotropins and SHBG. Irish Medical Journal 76 266-272.
25. Merritt MA & Cramer DW 2010 Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomarkers 9 287-305. (doi:10.3233/CBM- 2011-0167)
26. Merritt MA, De Pari M, Vitonis AF, Titus LJ, Cramer DW & Terry KL 2013 Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Human Reproduction 28 1406-1417. (doi:10.1093/humrep/des466)
27. Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S & Lidegaard O 2009 Hormone therapy and ovarian cancer. Journal of the American Medical Association 302 298-305. (doi:10.1001/jama.2009.1052)
28. O'Leary P, Boyne P, Flett P, Beilby J & James I 1991 Longitudinal assessment of changes in reproductive hormones during normal pregnancy. Clinical Chemistry 37 667-672.
29. Olsen CM, Green AC, Nagle CM, Jordan SJ, Whiteman DC, Bain CJ, Webb PM & Australian Cancer Study G & the Australian Ovarian Cancer Study G 2008 Epithelial ovarian cancer: testing the 'androgens hypothesis'. Endocrine-Related Cancer 15 1061-1068. (doi:10.1677/ERC-08-0075)
30. Ose J, Fortner RT, Rinaldi S, Schock H, Overvad K, Tjonneland A, Hansen L, Dossus L, Fournier A, Baglietto L et al. 2014 Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer [in press]. (doi:10.1002/ijc.29000)
31. Pearce CL, TemplemanC, RossingMA,LeeA,NearAM,WebbPM, NagleCM, Doherty JA, Cushing-Haugen KL, Wicklund KG et al. 2012 Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncology 13 385-394. (doi:10.1016/S1470-2045(11)70404-1)
32. Prat J 2012 Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Archiv 460 237-249. (doi:10.1007/s00428-012-1203-5)
33. Pukkala E 2011 Nordic biological specimen bank cohorts as basis for studies of cancer causes and control: quality control tools for study cohorts with more than two million sample donors and 130,000 prospective cancers. In Methods in Biobanking, pp 61-112. Ed J Dillner. New York, NY: Humana Press.
34. R Core Team 2014 Team R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing.
35. Rannevik G, Jeppsson S, Johnell O, Bjerre B, Laurell-Borulf Y & Svanberg L 1995 A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 21 103-113. (doi:10.1016/0378-5122(94)00869-9)
36. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM & Persson IR 2002 Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. American Journal of Epidemiology 156 363-373. (doi:10.1093/aje/kwf048)
37. Rinaldi S, Dossus L, Lukanova A, Peeters PH, Allen NE, Key T, Bingham S, Khaw KT, Trichopoulos D, Trichopoulou A et al. 2007 Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiology, Biomarkers & Prevention 16 23-29. (doi:10.1158/1055-9965.EPI-06-0755)
38. Risch HA 1998 Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Journal of the National Cancer Institute 90 1774-1786. (doi:10.1093/jnci/90.23.1774)
39. Risch HA, Marrett LD & Howe GR 1994 Parity, contraception, infertility, and the risk of epithelial ovarian cancer. American Journal of Epidemiology 140 585-597.
40. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, Dodge R & Hughes CL 1998 Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? Journal of the Society for Gynecologic Investigation 5 271-276. (doi:10.1016/S1071-5576(98)00017-3)
41. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A & Hughes C 1996 Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstetrics and Gynecology 88 554-559. (doi:10.1016/0029-7844(96)00226-8)
42. Speroff L & Marc AF 2005 Regulation of the menstrual cycle. In Clinical Gynecologic Endocrinology and Infertility, pp 187-231. Eds L Speroff & AF Marc. Baltimore, MD: Lippincott Williams & Wilkins.
43. Syed V, Ulinski G, Mok SC, Yiu GK & Ho SM 2001 Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Research 61 6768-6776.
44. Taylor RN & Lebovic DI 2004 The endocrinology of pregnancy. In Basic & Clinical Endocrinology, pp 637-657. Eds FS Greenspan & DG Gardner. New York, NY: Lange Medical Books/McGraw-Hill.
45. Teppo L, Pukkala E & Lehtonen M1994 Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncologica 33 365-369. (doi:10.3109/02841869409098430)
46. Thomas F, Renaud F, Benefice E, de Meeus T & Guegan JF 2001 International variability of ages at menarche and menopause: patterns and main determinants. Human Biology 73 271-290. (doi:10.1353/hub.2001.0029)
47. Trope CG, Kaern J & Davidson B 2012 Borderline ovarian tumours. Best Practice & Research. Clinical Obstetrics & Gynaecology 26 325-336. (doi:10.1016/j.bpobgyn.2011.12.006)
48. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, Lund E, Fournier A, Overvad K, Hansen L et al. 2011 Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. British Journal of Cancer 105 1436-1442. (doi:10.1038/bjc.2011.371)
49. Tworoger SS, Lee IM, Buring JE & Hankinson SE 2008 Plasma androgen concentrations and risk of incident ovarian cancer. American Journal of Epidemiology 167 211-218. (doi:10.1093/aje/kwm278)
50. Whitehead A & Whitehead J 1991 A general parametric approach to the meta-analysis of randomized clinical trials. Statistics in Medicine 10 1665-1677. (doi:10.1002/sim.4780101105)
51. Whiteman DC, Murphy MF, Cook LS, Cramer DW, Hartge P, Marchbanks PA, Nasca PC, Ness RB, Purdie DM & Risch HA 2000 Multiple births and risk of epithelial ovarian cancer. Journal of the National Cancer Institute 92 1172-1177. (doi:10.1093/jnci/92.14.1172)
52. Whittemore AS, Harris R & Itnyre J 1992 Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. American Journal of Epidemiology 136 1184-1203.
53. Wiegratz I, Jung-Hoffmann C & Kuhl H 1995 Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 51 341-346. (doi:10.1016/0010-7824(95)00098-U)
54. Worley MJ, Welch WR, Berkowitz RS & Ng SW 2013 Endometriosisassociated ovarian cancer: a review of pathogenesis. International Journal of Molecular Sciences 14 5367-5379. (doi:10.3390/ijms14035367)